More importantly, the patients with high expression of EZH2 and BMI1 are associated with the worst OS in TCGA, suggesting that inhibition of EZH2 and BMI1 activity by small inhibitors can be a promising therapeutic strategy for HCC. The gene discussed is EZH2; the disease is hepatocellular carcinoma.